Ethylene Glycol

Ethylene Glycol

SCHEMBL2115585

CCCCCCC(=O)OCC(C)OC(=O)CCCCCC.OCCO

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.66
ALDH1A1 P00352 1/20 0.66
PRKCA P17252 4/20 0.65
PRKCE Q02156 2/20 0.65
PRKCQ Q04759 2/20 0.65
PRKCD Q05655 2/20 0.65
MAPT P10636 2/20 0.63
KDM4E B2RXH2 1/20 0.59
DUSP3 P51452 1/20 0.59
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
MAPK1 P28482 1/20 0.56
LPAR1 Q92633 2/20 0.54
LPAR3 Q9UBY5 2/20 0.54
ENPP2 Q13822 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL16457 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL180497 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL6433273 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL56526 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL629793 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL1173235 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL141667 1.00 LMNA (0.66) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL9160363 0.98 LMNA (0.64) LMNAALDH1A1PRKCAPRKCEPRKCQ
Ethylene Glycol SCHEMBL12489211 0.98 LMNA (0.63) LMNAALDH1A1PRKCAPRKCEPRKCQ
Butane SCHEMBL3900185 0.97 LMNA (0.61) LMNAALDH1A1PRKCAPRKCEPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118948631-B Oil-in-water cleansing composition 深圳市护家科技有限公司 2025-02-14 CN claimed
CN-118948631-A Oil-in-water cleansing composition 深圳市护家科技有限公司 2024-11-15 CN claimed
CN-116370328-A Skin care composition and external skin preparation 深圳市护家科技有限公司 2023-07-04 CN claimed
EP-3280448-B1 ABIRATERONE ACETATE LIPID FORMULATIONS CAPSUGEL BELGIUM NV (BE) 2020-12-30 EP claimed
US-20200316093-A1 ABIRATERONE ACETATE LIPID FORMULATIONS CAPSUGEL BELGIUM NV (BE) 2020-10-08 US claimed
US-10722527-B2 Abiraterone acetate lipid formulations CAPSUGEL BELGIUM NV (BE) 2020-07-28 US claimed
US-10220223-B2 Cosmetic composition with a volumizing effect L'OREAL (FR) 2019-03-05 US claimed
US-20180125863-A1 ABIRATERONE ACETATE LIPID FORMULATIONS CAPSUGEL BELGIUM NV (BE) 2018-05-10 US claimed
EP-3280448-A1 ABIRATERONE ACETATE LIPID FORMULATIONS Capsugel Belgium NV (BE) 2018-02-14 EP claimed
WO-2016162229-A1 ABIRATERONE ACETATE LIPID FORMULATIONS CAPSUGEL BELGIUM N.V. (BE) 2016-10-13 WO claimed
EP-3010487-A1 NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION Contract Pharmaceuticals Limited (CA) 2016-04-27 EP claimed
US-9320693-B2 Cosmetic composition with a volumizing effect L'OREAL (FR) 2016-04-26 US claimed
WO-2014201541-A1 NON-AEROSOL FOAMS FOR TOPICAL ADMINISTRATION CONTRACT PHARMACEUTICALS LIMITED (CA) 2014-12-24 WO claimed
EP-1800650-B2 Cosmetic composition providing a voluminous effect OREAL (FR) 2013-08-14 EP claimed
EP-1800649-B2 Cosmetic composition with volumising effect OREAL (FR) 2012-10-10 EP claimed
WO-2011101239-A2 COSMETIC OR DERMATOLOGICAL USES OF A POWDER COMPRISING A FILLER, AN ESSENTIAL OIL AND A HYDROXYLATED ESTER OF POLYOL AND OF C4 TO C16 CARBOXYLIC ACID(S) L'OREAL (FR) 2011-08-25 WO claimed
EP-1800650-B1 Cosmetic composition providing a voluminous effect OREAL (FR) 2010-11-03 EP claimed
EP-1800649-B1 Cosmetic composition with volumising effect OREAL (FR) 2008-12-10 EP claimed
US-20070196301-A1 Cosmetic composition with a volumizing effect L'OREAL (FR) 2007-08-23 US claimed
US-20070141003-A1 Cosmetic composition with a volumizing effect L'OREAL (FR) 2007-06-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10722527-B2 Abiraterone acetate lipid formulations AR, CYP19A1, CYP46A1 LMNA 3660/4885ALDH1A1 1154/4885PRKCA 1072/4885
US-20200316093-A1 ABIRATERONE ACETATE LIPID FORMULATIONS AR, CYP19A1, CYP46A1 LMNA 3660/4885ALDH1A1 1154/4885PRKCA 1072/4885
US-20180125863-A1 ABIRATERONE ACETATE LIPID FORMULATIONS AR, CYP19A1, CYP46A1 LMNA 3660/4885ALDH1A1 1154/4885PRKCA 1072/4885
US-20070196301-A1 Cosmetic composition with a volumizing effect LIPA, CUTA, LIPG LMNA 388/4885ALDH1A1 2486/4885PRKCA 2438/4885
US-20070141003-A1 Cosmetic composition with a volumizing effect CUTA, ELOVL1, LIPA LMNA 483/4885ALDH1A1 2197/4885PRKCA 3394/4885
US-10220223-B2 Cosmetic composition with a volumizing effect CUTA, LIPA, LIPG LMNA 271/4885ALDH1A1 2312/4885PRKCA 2186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.